PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:20 2024-03-18 pm EDT 5-day change 1st Jan Change
2.895 EUR +0.52% Intraday chart for PHAXIAM Therapeutics S.A. -3.02% -37.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chart PHAXIAM Therapeutics S.A.
More charts
Following the merger with PHERECYDES in June 2023, ERYTECH Pharma S.A. has changed its corporate name to PHAXIAM Therapeutics S.A. The new group is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.895 EUR
Average target price
9.6 EUR
Spread / Average Target
+231.61%
Consensus